Better science. Better results.
With over 20 years’ experience as a Preclinical CRO, CBI has a range of oncology and tumor models suitable for your unique study needs.
- Angiogenesis, gene therapy, nanoparticle and stem cell capabilities
- Maximization of test article effectiveness and minimum effective dosage
- Combination therapies
- Comparison of formulation and routes of administration
- Maximum tolerated dose and pharmacokinetics/pharmacodynamics (MTD and PK/PD studies)
- Validated cell lines include but are not limited to:
- Breast: MDA-MB-231, MCF-7, 4T1
- Colon: Caco-2, HCT-116, COL 205, L5174T
- Lung: A549, Lewis Lung
- Prostate: LNCAP, PC-3, DU-145
- PDX models and other translational models
- Major Oncology Institute Collaborations
Our full service in vivo facility also offers:
- Toxicology and pharmacokinetic assessments
- On-site histopathology lab
- Immunohistochemistry
- Tissue cross reactivity studies
- In-house board-certified pathologist
- Efficient, quality reporting
Extensive experience with
- Small molecules
- Biologics
- Immunotherapy
- Stem cells
- Devices and implants
- Gene therapy
Standards of excellence
- GLP equipped
- AAALAC accredited
- USDA, FDA, and OLAW compliant
Fill out the form below to learn more about our oncology capabilities